University of Tennessee Internal Medicine Core Curriculum Lectures Lectures Include:
Management of Sickle Cell Disease – 12/18/07
Oncologic Emergencies – 10/07/06
Hemoglobinopathy – 6/21/05
Oncologic Emergencies – 04/19/05
2005 – Present
University of Tennessee Hematology/Medical Oncology Fellowship Program Teaching Staff Annual Lecture course load cover all of:
Colon and rectal cancer
Non-small cell lung cancer
2005 – Present
University of Tennessee Pulmonary Division Chest Conference – Multiple Presentations
2005 – Present
University of Tennessee Cancer Institute Noon Journal Club – Multiple Presentations
1999 – 2006
Amarillo Veterans Affairs Medical Center Decision Tumor Board Conference – Multiple Presentations
1996 – 1998
Teaching Assistant, University of Minnesota Spring Blood Course, Minneapolis, MN
1996 – 1998
University of Minnesota Garibaldi Research Conference – Multiple Presentations
1995 – 1998
University of Minnesota Grand Rounds – Multiple Presentations
1995 – 1998
Minneapolis Veterans Affairs Medical Center Grand Rounds – Multiple Presentations
1995 – 1998
Hennepin County Medical Center Grand Rounds – Multiple Presentations
GRAND ROUNDS AND OTHER INTRAMURAL PRESENTATIONS:
‘The Quality of Surgical Resection for Lung Cancer in the Memphis Metropolitan Area’, University of Tennessee Medicine Grand Rounds
‘Management of Colorectal Liver Metastases’, University of Tennessee-Chattanooga Grand Rounds.
‘The Multidisciplinary Thoracic Oncology Clinic’, University of Tennessee Medicine Grand Rounds
‘Management of Superior Sulcus Tumors’, Methodist University Hospital Tumor Conference
‘The Vasculopathy of Sickle Cell Disease’, University of Tennessee Endocrinology Grand Rounds
‘Evolving Ideas About Sickle Cell Disease: Old Wine, New Skin’, University of Tennessee Medicine Grand Rounds
‘Understanding United States Cancer Statistics’, Texas Tech University Health Science Center Grand Rounds
‘Heparin-Induced Thrombocytopenia’, Texas Tech University Health Science Center Grand Rounds
‘Ignorant Armies Clash by Night: The Antiphospholipid Antibody Syndrome’, Texas Tech University Health Science Center Grand Rounds
‘Approach to the Bleeding Patient’, Texas Tech University Health Science Center Grand Rounds
‘Bad Humors from Dying Cancer Cells: Tumor Lysis Syndrome’, Texas Tech University Health Science Center Grand Rounds
‘The Hypereosinophilic Syndrome’, Texas Tech University Health Science Center Grand Rounds
VISITING PROFESSORSHIPS AND INVITED LECTURES:
Amarillo, Tx. September 2010, “Lung Cancer: From Nodule to Diagnosis”, Texas Tech University Fall Cancer Symposium Visiting Professor.
San Francisco, CA, August 1, 2009, “Surgery Allowing Neoadjuvant Treatment of N2 NSCLC”, Discussant at proffered paper session, 13th World Conference on Lung Cancer.
Memphis, TN, September 2008, “Preventive Care for the Sickle Cell Patient”, First Annual Health Fair and Sickle Cell Awareness Day, National Civil Rights Museum.
Memphis, TN, September 2008, “Managing Sickle Cell Disease as a Chronic Health Problem”, First Annual Health Fair and Sickle Cell Awareness Day, National Civil Rights Museum.
Palm Beach, FL, April 2008, “Setting Up Thoracic Multidisciplinary Clinics: The University of Tennessee Cancer Institute Experience”, Tenth Annual Palm Beach Cancer Symposium.
Memphis, TN, October 2007, “The Mid-South Thoracic Multidisciplinary Clinic: Implementation and Results”, Fifth Annual Mid-South Cancer Symposium: Focus on Thoracic Oncology.
Amarillo, TX, September 2007, “Screening for Lung Cancer: Past, Present and Future”, Amarillo Fall Cancer Symposium Visiting Professor.
Memphis, TN, September 2005, “Treatment Strategies for Transfusional Iron Overload”, Memphis Oncology Journal Club.
Memphis, TN, May 2005, “Cancer Prevention and Screening”, American Cancer Society Public Information Symposium.
Amarillo, TX, April 2005, “Epidemiology of Lung Cancer”, Texas Tech University/American Cancer Society Lung Cancer Symposium.
Memphis, TN, May 2004, “The Early Multidisciplinary Approach to Lung Cancer”, University of Tennessee Cancer Institute.
Amarillo, TX, November 2003, “Prometheus Bound: Screening for Lung Cancer”, American Cancer Society Symposium.
Amarillo, TX, June 2003, “Primary Care Symposium: Colorectal Cancer Screening Initiative”, Amarillo Veterans Affairs Healthcare System.
Amarillo, TX, July 2001, “The Endothelial Biology of Sickle Cell Disease”, Texas Tech University Health Sciences Center.
Minneapolis, MN, June 1999, Paper Presentation at the University of Minnesota Bone Marrow Transplant Research Conference.
ABSTRACTS PRESENTED IN THE US:
Surgical lymph node clearance and pathologic evaluation in gastric cancer. A Khattak, JC Sachdev, MC Evangelist, J Denbo, W.S Orr, M Ul-Haq, A Farooq, AC Thompson, RA Dilawari, RU Osarogiagbon. Abstract #131, 2011 Gastrointestinal Cancers Symposium, San Francisco, CA. January 2011.
A comparison of surgical resection for distal esophageal, gastroesophageal and proximal gastric cancer in the Memphis Metropolitan Area. MC Evangelist, WS Orr, M Ul-Haq, A Farooq, A Khattak, J Denbo, A Mahmoud, RA Dilawari, JC Sachdev, RU Osarogiagbon. Abstract #147, 2011 Gastrointestinal Cancers Symposium, San Francisco, CA. January 2011.
Pattern of gastric cancer resection in the Memphis metropolitan area (MMA). Evangelist, Sachdev, Khattak, Denbo, Orr, Ul-Haq, Berry, O'Brien, Dilawari, Osarogiagbon. E-poster 14633, abstract #54690 presented at the American Society of Clinical Oncology annual meeting 2010.
Maruyama index (MI) and outcomes of gastric cancer resection. Sachdev, Evangelist, Orr, Denbo, Khattak, Ul-Haq, Farooq, Thompson, Mahmoud, Osarogiagbon. J Clin Oncol 2010; 15s: 339s. Abstract #4154, presented at the American Society of Clinical Oncology annual meeting 2010.
Evaluation of multidisciplinary (multiD) care in thoracic oncology. Phelps, Bankole, Sarwar, McFarlane, Osarogiagbon. J Clin Oncol 2010; 15s: 470s. Abstract #6093, presented at the American Society of Clinical Oncology annual meeting 2010.
Surgeon-determined variability in quality of surgical resection of lung cancer. Ramirez, Farooq, Allen, Berry, O’Brien, Cole, Osarogiagbon. J Clin Oncol 2010; 15s: 531s. Abstract #7068, presented at the American Society of Clinical Oncology annual meeting 2010.
Review of mediastinal lymph node examination (mLNE) in a lung cancer resection (LCR) cohort. Osarogiagbon, Allen, Farooq, O’Brien, Wu. J Clin Oncol 2010; 15s: 531s. Abstract #7070, presented at the American Society of Clinical Oncology annual meeting 2010.
A single arm phase 2 study of enzastaurin in combination with erlotinib, both administered orally daily, to patients with advanced non-small cell lung cancer (NSCLC). Wakelee, Dubey, Krupitskaya, Osarogiagbon, Sanborn, Bernstein, Dudek, Latz, Yuan, Natale. Presented at the World Conference on Lung Cancer 2009: PD3.2.2
Clinical implications and determinants of inaccurate pathologic staging of lung cancaer in a large US metropolitan area. Farooq, Allen, O’Brien, Ratliff, Ninan, Osarogiagbon. Presented at the World Conference on Lung Cancer 2009: PD6.5.2
Number of lymph nodes examined and likelihood of lymph node positivity after resection of lung cancer. Osarogiagbon, Allen, Farooq, O’Brien, Spencer, Ratliff, Ninan. Presented at the World Conference on Lung Cancer 2009: 12.1.2
Quantification of the difficulty of accruing patients into quality-restrictive post-resection clinical trials for non-small cell lung cancer (NSCLC). Allen, Farooq, Ramirez, Ninan, Osarogiagbon. Presented at the World Conference on Lung Cancer 2009: 12.3.3
Objective review of surgeon reported lymph node dissection after resection of lung cancer in a US metropolitan area. Ninan, Wu, Allen, Farooq, Kernstine, Osarogiagbon. Presented at the World Conference on Lung Cancer 2009: C4.4
Outcome of surgical resection for pathologic Nx and N0 non-small cell lung cancer (NSCLC). Osarogiagbon, Allen, Farooq, Ninan, Ratliff. Presented at the American Society of Clinical Oncology annual meeting 2009.
Accuracy and comprehensiveness of pathology reportage after lung cancer resection. Farooq, Osarogiagbon, Allen, O’Brien, Spencer, Berry. Presented at the American Society of Clinical Oncology annual meeting 2009.
Quality of surgical resection for non-small cell lung cancer (NSCLC) in a US metropolitan area. Allen, Osarogiagbon, Farooq, Ninan, O’Brien. Presented at the American Society of Clinical Oncology annual meeting 2009.
A comparison of two models of care for lung cancer. Osarogiagbon, Ninan, McFarlane, Bankole, Smeltzer, Jahanzeb. J Clin Oncol 2008, ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2009: 17501.
Pattern of Adjuvant Chemotherapy for Stage II Colon Cancer in a University-Based Oncology Practice. Khattak, Sachdev, Osarogiagbon. Orlando, FL, January 2008, Gastrointestinal Cancers Symposium.
The Prevalence of Renal Dysfunction in Young Adults with Sickle Cell Disease. Osarogiagbon, Chismark. 49th ASH Annual Meeting and Exposition, Atlanta, GA 2007.
Hand-Assisted vs Open Colectomy in a Non-tertiary Care Setting. Osarogiagbon, Ogbeide, Ogbeide, George. GI Cancers Symposium, Orlando, FL January 2007.
Screening Experience of Patients Diagnosed with Colorectal Cancer (CRC). Osarogiagbon. Gastrointestinal Cancers Symposium, Hollywood, FL, January 2005.
Burkitt’s Lymphoma Occurring Less Than One Month After Chemotherapy for H. Pylori-associated Diffuse Large Cell Lymphoma. Osarogiagbon. Annual Convention of the American Society of Hematology, New Orleans, LA, December, 1999.
CMV Antigenemia after BMT: Risk Factors and Clinical Outcomes. Osarogiagbon, Defor, Erice, Weisdorf. American Society of Hematology Annual Convention. Miami Beach, FL, December 9, 1998.
Evidence of Reperfusion Injury Physiology in a Transgenic Mouse Model of Sickle Cell Disease. Osarogiagbon, Choong, Paller, Vercelotti, Hebbel. American Society of Hematology Annual Convention. San Diego, CA, December 1997.
Sickle Cell Anemia s an Example of Reperfusion Injury Physiology: Studies in Transgenic Mice. Osarogiagbon, Choong, Paller, Vercelotti, Hebbel. 25th Annual Meeting of the National Sickle Cell Program, Washington, DC, September 1997.
ABSTRACTS PRESENTED AT INTERNATIONAL MEETINGS:
Palais des Congres de Paris, April 2008, “Implementation of a Multidisciplinary Clinic Care Model for Lung Cancer”, International Forum on Quality and Safety in Health Care.
Seoul, South Korea, September 2007, “Concordance Between Recommendations of a Multidisciplinary Thoracic Oncology Conference and Actual Clinical Practice”, 12th World Conference on Lung Cancer.
Barcelona, Spain, June 2005, “Comparison of Hand-assisted Laparoscopic and Open Colectomy for Colon Tumors”, World Congress on Gastrointestinal Cancer.
Associate Editor, Archives of Ibadan Medicine
Member, Faculty of 1000
Manuscript reviewer: Annals of Thoracic Surgery Diseases of the Esophagus Journal of Thoracic Oncology
EXTERNAL GRANT REVIEWER FOR FUNDING AGENCY:
Randomized Controlled Trials Unit of the Canadian Institutes of Health Research
National Comprehensive Cancer Network Esophageal Guidelines Panel (2005 – present)
National Comprehensive Cancer Network Gastric Guidelines Panel (2005 – present)
National Comprehensive Cancer Network Genetic/Familial High Risk Assessment Guidelines Panel (2005-2008)
National Comprehensive Cancer Network Non-Small Cell Lung Cancer Guidelines Panel (2008 - present)
American Society of Hematology Outreach Sub-Committee on Africa (1999-2001)
Southwest Oncology Group Health Disparities Committee.
Southwest Oncology Group Gastrointestinal Cancers Committee.
Southwest Oncology Group Lung Cancer Committee.
University of Tennessee Fellowship Training Program Committee
Laura Beth Miller, MD. Department of Medicine, University of Tennessee, Memphis.
Christopher Wang, MD. Department of Medicine, University of Tennessee, Memphis.
Aamer Farooq, MD. Roswell Park Cancer Institute, Buffalo NY.
Olufunsho Bankole, MBBS. Division of Pulmonary and Critical Care Medicine. University of Tennessee, Memphis.
Elisabeth Chismark, UT College of Nursing, successful nursing Phd candidate. I co-mentored her project titled ‘Characteristics of secondary complications and the association of serum c-reactive protein levels and a genetic c-reactive protein polymorphism in adult sickle cell patients’ with Ann Cashion, Phd.
Jianquan Zhu, MD, Thoracic Surgeon, Guangdong Provincial People’s Hospital, Guangzhou, Guangdong, China. June 2008. American Society of Clinical Oncology (ASCO) International Development and Education Award (IDEA) Program.
Roderigo Dienstmann, Medical Oncologist, National Institutes of Health of Brazil. June 2007 ASCO IDEA Program.
RESEARCH AND OTHER EXTERNAL SUPPORT:
Feasibility study of the use of special specimen collection kit to improve lymph node yield during surgical resection of non-small cell lung cancer. Funded by the Methodist Healthcare Foundation. $30,000. Ongoing.
Systematic Review of the Product of Surgical Resection in the Memphis Metropolitan Area (MMA): OSI-TAR-763. Funded to $55,750. Principal Investigator. On-going project.
Phase II multicenter study of temsirolimus in patients with advanced hepatocellular cancer (HCC) previously treated with sorafenib. Principal Investigator: Jasgit Sachdev, MD, Raymond Osarogiagbon, MD. Funding Agency: Wyeth Pharmaceuticals. Funding approved to $298,170.
CURRENT RESEARCH INTERESTS:
The relationship between models of care, access and outcomes in the management of lung cancer.
The determinants of the pattern and quality of surgical resection for lung cancer, esophageal and gastric cancer.
The pattern of use of adjuvant chemotherapy for colon cancer.
Implementation of an adult sickle cell program in the greater Memphis area, in collaboration with St. Jude Children’s Research Hospital’s Comprehensive Sickle Cell Program.
Dilineating the full picture of cumulative and chronic organ damage in sickle cell disease.
National Cancer Institute Investigator number: 28258
Southwest Oncology Group investigator number: 34995
Institutional Principal Investigator (University of Tennessee) for the Southwest Oncology Group (SWOG)
E1505: Chemotherapy with or without bevacizumab in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. National Cancer Institute-sponsored trial under the auspices of the Eastern Cooperative Oncology Group. ClinicalTrials.gov identifier: NCT00324805.
SWOG 0533: A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer. Southwest Oncology Group and National Cancer Institute-sponsored trial. ClinicalTrials.gov identifier: NCT00334815.
OSI 774-302: RADIANT: A Multi-Center Ranodmized, Double-Blind, Placebo-Controlled, Phase III Study of Single-Agent Tarceva (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR-positive Tumors. Sponsored by OSI Pharmaceuticals. ClincalTrials.gov identifier: NCT00373425.
Lilly H6Q-MC-S030: A Phase I/II Trial of Enzastaurin and Erlotinib in Patients with Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) after Prior Chemotherapy.
GSK HYT11127: An Open-label, Multicenter, Non-comparative, Phase II Study of Oral Topotecan in Combination with Bevacizumab for Second-line Treatment in Subjects with Relapsed Small-Cell Lung Cancer (SCLC).
Merck 056-02: A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Small Cell Lung Cancer (NSCLC).
CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucorovin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. National Cancer Institute-sponsored intergroup trial. ClinicalTrials.gov identifier: NCT00265850.
SWOG 0600: Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer Who Have Progressed on Bevacizumab with Either FOLFOX, Optimox or XeLOX. National Cancer Institute-sponsored intergroup trial. ClinicalTrials.gov identifier: NCT00499369.
ECOG E5204: Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pro-Operative Chemoradiation.
NSABP R-04: A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum.
A feasibility study of the use of a special specimen collection kit to improve lymph node yield during surgical resection of non-small cell lugn cancer.
Pathologic examination of resected lung cancer: A pilot study to improve staging.
Systematic Review of the Product of Surgical Resection of Lung Cancer in the Memphis Metropolitan Area (MMA): funded by OSI. Budget: $55,750
Concordance Between Management Recommendations of a Multidisciplinary Lung Cancer Board and Clinical Management.
Healthcare disparities and lung cancer: The Memphis experience: moderating disparities by means of the early multidisciplinary model of care.
Phase II trial of bevacizumab + standard platinum-based combination chemotherapy and radiation therapy for non-surgically resectable stage IIIA and IIIB non-small cell lung cancer.
Impact of adjuvant chemotherapy on 5-year survival outcomes of patients with stage IIB vs. IIIA colon cancer: a SEER/Medicare linked database analysis.
Prevalence and predictors of chronic organ damage in adults with sickle cell disease.
Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer. Osarogiagbon RU, Allen JW, Farooq A, Berry A, O’Brien T. Accepted for publication in the Annals of Thoracic Surgery.
Causes and consequences of deviation from multidisciplinary care in thoracic oncology. Osarogiagbon RU, Phelps G, McFarlane J, Bankole O. Accepted for publication in the Journal of Thoracic Oncology.
Quality of surgical resection for nonsmall cell lung cancer in a US metropolitan area. Allen JW, Farooq A, O'Brien TF, Osarogiagbon RU. Gastric cancer. Cancer. 2011;117:134-42. Published online August 24, 2010. DOI 10.1002/cncr.25334. PMID: 20737568.
Thymic Malignancies. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. J Natl Compr Canc Netw. 2010 Nov 1;8(11):1302-1315. PMID: 21081786
Non-small cell lung cancer. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC. J Natl Compr Canc Netw. 2010 Jul;8(7):740-801.